Trials / Completed
CompletedNCT02473900
Evaluating the Bioequivalence of HIP1403, HGP0919
An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics of HIP1403 in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- Male
- Age
- 19 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the bioequivalence after administration of HIP1403 and HGP0919 in healthy male volunteers
Detailed description
A randomized, open-label, single dose, crossover clinical trial to investigate and compare the pharmacokinetics between HIP1403 and HGP0919 in healthy male volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HIP1403 | Oseltamivir 75mg |
| DRUG | HGP0919 | Oseltamivir phosphate 75mg |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2015-04-01
- Completion
- 2015-04-01
- First posted
- 2015-06-17
- Last updated
- 2016-10-13
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02473900. Inclusion in this directory is not an endorsement.